SOShu Okugawa

Shu Okugawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shu Okugawa has a total of 406 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort

    by Masahiro Arima, Shinya Yamamoto, Maho Adachi-Katayama, Koh Okamoto, Masahiko Ando, Shu Okugawa, Minoru Ono, Takeya Tsutsumi

    Vaccination is among the cornerstones of infectious disease prevention in heart transplant candidates and recipients. Guidelines recommend an inactivated hepatitis A virus vaccine for heart transplant candidates, many of whom are on ventricular assist devices and at risk of hepatitis A virus exposure. However, data on the immunogenicity and safety of hepatitis A virus vaccines in these patients are lacking.This retrospective, observational, single-center study was conducted at our outpatient clinic between December 2019 and December 2025. The study participants were heart transplant candidates with ventricular assist devices aged ≥16 years who tested negative for anti-hepatitis A virus immunoglobulin G at baseline and completed the inactivated hepatitis A virus vaccination series. Anti-hepatitis A virus immunoglobulin G titers were measured after vaccination using a chemiluminescent immunoassay. Thirty-five individuals were included in the study. Immunosuppressive agents were used in four patients (11.4%). All participants achieved seroconversion at a median of 1 month after vaccination. The reverse cumulative distribution of the Anti-hepatitis A virus immunoglobulin G sample/cutoff values indicated that an adequate antibody response was achieved in individuals with ventricular assist devices. Adverse events of the vaccine were minor; two patients (6%) experienced local pain, and two (6%) subcutaneous hemorrhage. Seroconversion in patients with ventricular assist devices was high. hepatitis A virus vaccination should be completed before transplantation in heart transplant candidates, if indicated.

  • Open Access

    Erratum for Okutani et al., "Genetic diversity and virulence of Bacillus cereus group isolates from bloodstream infections"

    by Akiko Okutani, Shu Okugawa, Fumie Fujimoto, Mahoko Ikeda, Takeya Tsutsumi, Kyoji Moriya, Ken Maeda

  • Open Access

    Genetic diversity and virulence of Bacillus cereus group isolates from bloodstream infections

    by Akiko Okutani, Shu Okugawa, Fumie Fujimoto, Mahoko Ikeda, Takeya Tsutsumi, Kyoji Moriya, Ken Maeda

    Bacillus cereus catheter-related bloodstream infections (CRBSIs) are an increasing concern in Japanese hospitals. Although their clinical characteristics have been explored, the genetic relationships and virulence profiles of B. cereus isolates from CRBSIs remain understudied. Here, using advanced genomic techniques, we investigated the genetic diversity, phylogenetic relationships, and virulence profiles of B. cereus isolates from patients with bloodstream infections. We analyzed 28 B. cereus group strains isolated from blood samples at the University of Tokyo Hospital between 2005 and 2017 using whole-genome sequencing, core-genome single-nucleotide polymorphism (SNP) typing, and virulence gene profiling. Core-genome SNP analysis revealed significant genetic diversity among the isolates, suggesting multiple independent sources of infection. The isolates predominantly belonged to panC clades III and IV, with distinct virulence gene profiles. All panC clade III isolates contained hbl operon genes, whereas four isolates from clade IV harbored cereulide synthetase genes ( cesABCD ). One isolate possessed a capsule gene operon ( capBCADE ), a rare finding among clinical B. cereus strains. Biofilm formation ability was observed in 50% of catheter-related isolates, although this ability was not significantly different from that of the noncatheter-related isolates. IMPORTANCE: This study provides novel insights into the genetic diversity and virulence potential of B. cereus strains causing bloodstream infections in a Japanese hospital setting. These findings suggest diverse infection pathways and highlight the importance of continuous molecular epidemiological surveillance for effective infection control.


  • Open Access

    Epidemiology and risk factors for mortality in clostridial bacteremia in Japan: A retrospective multicenter observational study

    by Aiko Okazaki, Shu Okugawa, Tatsuya Kobayashi, Miki Kawada, Kyotaro Kawase, Shin Nakayama, Yoshitaka Wakabayashi, Takatoshi Kitazawa, Riko Takezawa, Keita Tatsuno, et al.


  • Open Access

    Clinical impact of the use of chronic suppressive antibiotics against recurrent ventricular assist device infections

    by Shinya Yamamoto, Koh Okamoto, Hiraku Kumamaru, Makoto Saito, Hiroshi Ito, Marie Yamashita, Yoshiaki Kanno, Mahoko Ikeda, Sohei Harada, Shu Okugwa, et al.

    Ventricular assist device (VAD) infections are frequent causes of hospital readmission. The risk factors and optimal preventive strategies for such, including chronic suppressive antibiotics (CSA), remain uncertain. We performed a single-center, retrospective, observational cohort study assessing continuous flow VAD recipients who underwent implantation between 2008 and 2018 in Japan. From primary VAD infection (VADI), we followed the patients for recurrent infection, defined as relapsing VAD-specific (e.g., localized infections) or VAD-related (e.g., bacteremia) infections requiring hospital readmission. CSA was defined as the use of oral antimicrobial agents continued beyond initial antibiotic use until transplantation, VAD withdrawal, VADI recurrence, or death. Survival analysis was performed to identify risk factors for recurrent infection accounting for competing risks (e.g., deaths and transplants). Among 163 eligible patients, 76 patients had VADIs. The main causative organism in primary VADI was Staphylococcus aureus (63%, 48/76). Among them, 41 had recurrent infections, whereas 35 had none during the follow-up period (median, 335 days). Thirty-six patients received CSA for a median of 478 days. Although CSA was associated with a decreased risk of recurrent infection [adjusted sub-distribution hazard ratio (SHR), 0.40; 95% confidence interval (CI), 0.18–0.89; P = 0.03], this protective effect was observed only after primary VAD-specific infection (SHR, 0.28; 95% CI, 0.12–0.64; P < 0.01) but not after VAD-related infection. Surgical procedures during primary VADI were associated with an increased risk (SHR, 2.00; 95% CI, 1.10–3.66; P = 0.02). One patient had an adverse drug reaction. CSA may be an effective approach to limit relapsing VADIs following a primary VAD-specific infection with minimal adverse events. IMPORTANCE: Ventricular assist device infections (VADIs) are a significant complication leading to hospital readmissions. However, the risk factors and optimal preventive strategies for VADI remain unclear. This study investigated the effectiveness of chronic suppressive antibiotic therapy in patients with VADI. We found that the use of chronic suppressive antibiotic therapy was associated with a reduction in the risk of VADI recurrence with few adverse reactions. Our findings suggest the potential benefit of chronic suppressive antibiotics in preventing infections in selected cases. Our findings are relevant for the management of patients with ventricular assist devices awaiting heart transplantation, providing valuable insights for clinical practice.


  • Carbon dioxide-dependent, extended-spectrum β-lactamase producing Escherichia coli bacteremia associated with pyelonephritis: A case-report

    by Shinya Yamamoto, Tatsuya Kobayashi, Mahoko Ikeda, Yusuke Nomura, Takeru Morishige, Katsuhiro Makino, Hiroshi Ito, Marie Yamashita, Daisuke Jubishi, Yoshiaki Kanno, et al.

  • Open Access

    Draft genome sequence including the capsule operon of a Bacillus cereus strain isolated from a patient with bacteremia in Japan

    by Akiko Okutani, Shu Okugawa, Fumie Fujimoto, Mahoko Ikeda, Takeya Tsutsumi, Kyoji Moriya, Ken Maeda

    Bacillus cereus, which causes opportunistic infections in hospitals as well as food poisoning, is genetically similar to Bacillus anthracis. We herein report the draft genome including the capsule operon of B. cereus BCER1 isolated from the blood of a hospital patient in Japan.


  • Open Access

    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)

    by Takeshi Arashiro, Maki Miwa, Hidenori Nakagawa, Junpei Takamatsu, Kunihiro Oba, Satoshi Fujimi, Hitoshi Kikuchi, Takamasa Iwasawa, Fumiko Kanbe, Keisuke Oyama, et al.


  • Open Access

    2570. The intraoperative pharmacokinetics of ampicillin and sulbactam and the effect of massive bleeding in recipients of living donor liver transplantation

    by Yuji Wakimoto, Koh Okamoto, Takehito Yamamoto, Nobuhisa Akamatsu, Taro Kariya, Yoko Hoshino, Sohei Harada, Hideki Hashimoto, Daisuke Jubishi, Ryo Yamaguchi, et al.

    The current guidelines recommend redosing of prophylactic intraoperative antimicrobials based on their half-life or in case of bleeding greater than 1,500 mL. However, data to support this practice is scarce. Orthotopic liver transplantation is often accompanied by massive bleeding. Therefore, we aimed to characterize the intraoperative pharmacokinetics of the prophylactic antimicrobial to analyze the pharmacokinetic parameters in recipients of living-donor liver transplantation (LDLT). The recipients of LDLT who were 20 years or older without allergy to any beta-lactams were included. All participants received intravenous ampicillin-sulbactam (ABPC-SBT) 2-1 gram one hour before and every three hours during surgery over 30 minutes. The amount of blood loss and relevant parameters were recorded. Blood samples were collected every hour during surgery. The total plasma concentrations of ABPC and SBT were determined using a liquid chromatography-tandem mass spectrometry. Noncompartmental analysis was applied to calculate the clearances of ampicillin and sulbactam. The probability of target attainment (PTA) was determined based on the breakpoints proposed by The Clinical Laboratory Standards Institute assuming that the protein binding rate of ABPC and SBT were 28% and 38%, respectively. Twenty recipients were included (Table). The median age, weight, and amount of blood loss of the recipients were 52 years, 62.1 kg, and 11,158 mL, respectively. A median of calculated creatinine clearance were 99.6 mL/min. The total concentrations of ABPC and SBT in plasma and the amount of blood loss are shown (Figure 1, 2). Twelve participants (60%) achieved the PTA of 100% in both ABPC and SBT during surgery. The model-independent clearances of ABPC and SBT were 80.3 and 77.2 mL/min, respectively. Although bleeding greater than 20,000mL tended to increases the clearances of ABPC and SBT, the overall time above minimum inhibitory concentration of common pathogens was at acceptable level during surgery. Characteristics of 20 living-donor liver transplantation recipients. *Chronic hepatitis B, chronic hepatitis D, and autoimmune hepatitis ** Recipients on renal replacement therapy were excluded. Characteristics of 20 living-donor liver transplantation recipients. *Chronic hepatitis B, chronic hepatitis D, and autoimmune hepatitis ** Recipients on renal replacement therapy were excluded. Intraoperative redosing of ABPC-SBT every three hours achieved the PTA of 100% in 60% of the LDLT recipients despite intraoperative massive bleeding. All Authors: No reported disclosures

  • Open Access

    Comparison of phylogenetic and virulence factors between Escherichia coli isolated from biliary tract infections and uropathogenic Escherichia coli

    by Mahoko Ikeda, Tatsuya Kobayashi, Shu Okugawa, Fumie Fujimoto, Yuta Okada, Keita Tatsuno, Yoshimi Higurashi, Takeya Tsutsumi, Kyoji Moriya